Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaccinology in pediatric rheumatology: Past, present and future.
Bizjak M, Heshin-Bekenstein M, Jansen MHA, Ziv A, Angevare S, Uziel Y, Wulffraat NM, Toplak N; PReS Vaccination Working Party. Bizjak M, et al. Among authors: uziel y. Front Pediatr. 2023 Jan 10;10:1098332. doi: 10.3389/fped.2022.1098332. eCollection 2022. Front Pediatr. 2023. PMID: 36704144 Free PMC article. Review.
Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study.
Heshin-Bekenstein M, Ziv A, Toplak N, Lazauskas S, Kadishevich D, Ben-Nun Yaari E, Miller-Barmak A, Butbul Aviel Y, Saiag E, Pel S, Elkayam O, Uziel Y, Furer V. Heshin-Bekenstein M, et al. Among authors: uziel y. Vaccines (Basel). 2023 Apr 10;11(4):819. doi: 10.3390/vaccines11040819. Vaccines (Basel). 2023. PMID: 37112731 Free PMC article.
Editorial: Vaccination in children with immune-mediated diseases.
Toplak N, Wulffraat NM, Uziel Y. Toplak N, et al. Among authors: uziel y. Front Pediatr. 2023 Apr 14;11:1192407. doi: 10.3389/fped.2023.1192407. eCollection 2023. Front Pediatr. 2023. PMID: 37124191 Free PMC article. No abstract available.
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutová Š, Antón J, Wang Z, Meszaros G, Araújo J, Liao R, Keller S, Brunner HI, Ruperto N; JUVE-BASIS investigators; Paediatric Rheumatology International Trials Organisation. Ramanan AV, et al. Lancet. 2023 Aug 12;402(10401):555-570. doi: 10.1016/S0140-6736(23)00921-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423231 Clinical Trial.
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ; PRINTO; PRCSG. Ruperto N, et al. Among authors: uziel y. N Engl J Med. 2012 Dec 20;367(25):2396-406. doi: 10.1056/NEJMoa1205099. N Engl J Med. 2012. PMID: 23252526 Free article. Clinical Trial.
196 results